Drug Profile
Bevacizumab biosimilar - AryoGen Pharmed
Alternative Names: AryoGen Pharmed; StivantLatest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator AryoGen Biopharma
- Developer AryoGen Pharmed
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer
Most Recent Events
- 22 Feb 2022 Bevacizumab biosimilar is still in phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy) in Iran (IV)
- 22 Aug 2016 Phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy) in Iran (IV) (IRCT2015072517994N2)